GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.629
EU - Europa 4.683
AS - Asia 2.645
SA - Sud America 343
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 55
OC - Oceania 52
Totale 15.478
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.510
RU - Federazione Russa 1.494
PL - Polonia 996
IT - Italia 796
SG - Singapore 744
CN - Cina 601
HK - Hong Kong 444
IE - Irlanda 361
SE - Svezia 314
VN - Vietnam 304
BR - Brasile 267
KR - Corea 195
FI - Finlandia 189
DE - Germania 158
FR - Francia 120
GB - Regno Unito 92
IN - India 82
CA - Canada 74
JP - Giappone 52
AU - Australia 51
UA - Ucraina 47
TR - Turchia 43
ID - Indonesia 41
AR - Argentina 32
JO - Giordania 30
CI - Costa d'Avorio 26
BD - Bangladesh 25
NL - Olanda 23
ES - Italia 22
MX - Messico 21
EC - Ecuador 17
BE - Belgio 16
IQ - Iraq 16
CO - Colombia 14
ZA - Sudafrica 13
AE - Emirati Arabi Uniti 10
PK - Pakistan 10
MA - Marocco 9
CH - Svizzera 8
CZ - Repubblica Ceca 8
RO - Romania 8
CR - Costa Rica 6
EG - Egitto 6
SA - Arabia Saudita 6
HN - Honduras 5
LT - Lituania 5
PH - Filippine 5
AZ - Azerbaigian 4
JM - Giamaica 4
NG - Nigeria 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
DK - Danimarca 3
KE - Kenya 3
LB - Libano 3
MT - Malta 3
PE - Perù 3
TH - Thailandia 3
UZ - Uzbekistan 3
AL - Albania 2
AM - Armenia 2
BB - Barbados 2
BY - Bielorussia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
MD - Moldavia 2
MM - Myanmar 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AT - Austria 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BM - Bermuda 1
BO - Bolivia 1
CG - Congo 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
IL - Israele 1
IR - Iran 1
LK - Sri Lanka 1
LV - Lettonia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 15.418
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.682
Warsaw 991
Ashburn 850
Fairfield 548
Singapore 526
San Jose 436
Hong Kong 362
Dublin 361
Chandler 296
Woodbridge 264
Seattle 231
Cambridge 227
Beijing 226
Wilmington 218
Houston 199
Seoul 192
Ann Arbor 146
Council Bluffs 140
Milan 120
The Dalles 120
Altamura 105
Buffalo 104
Lawrence 95
Florence 94
Princeton 94
Ho Chi Minh City 89
Helsinki 87
Los Angeles 81
Lauterbourg 78
Jacksonville 76
Rome 62
Hanoi 59
Boardman 57
Boston 57
Bremen 52
Munich 52
Medford 51
Dallas 50
Mumbai 50
New York 50
Hefei 47
Tokyo 47
Melbourne 45
Shanghai 40
Moscow 35
San Diego 34
Dong Ket 32
Falls Church 31
Turku 29
Izmir 28
Jakarta 28
Abidjan 26
São Paulo 26
Phoenix 22
Chicago 21
Clifton 21
Paris 21
London 20
Naples 19
Norwalk 19
Washington 16
Brussels 15
Brooklyn 14
Montreal 14
Redondo Beach 14
Andover 11
Atlanta 11
Orem 11
Turin 11
Guangzhou 10
Palermo 10
Barcelona 9
Bologna 9
Da Nang 9
Frankfurt am Main 9
Kent 9
Modena 9
Toronto 9
Bari 8
Bern 8
Guayaquil 8
Hải Dương 8
Verona 8
Brasília 7
Haiphong 7
Hillsboro 7
Miano 7
Nanjing 7
Quito 7
Salerno 7
Stockholm 7
Amsterdam 6
Baghdad 6
Cagliari 6
Curitiba 6
Denver 6
Detroit 6
Figino 6
Istanbul 6
Johannesburg 6
Totale 10.519
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 339
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 324
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 308
HCV and lymphoproliferation 288
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 278
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 266
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 265
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 264
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 263
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 242
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 241
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 241
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 238
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 237
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 235
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 232
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 232
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 220
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 216
Host genetic determinants in HCV-related mixed cryoglobulinemia 215
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 215
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 207
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 206
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 206
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 203
Host genetic determinants in HCV-related mixed cryoglobulinemia 202
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 197
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 195
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 191
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 191
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 190
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 187
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 186
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 181
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 180
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 178
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 178
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 178
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 176
Host genetic determinants in HCV-related mixed cryoglobulinemia 175
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 172
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 169
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 168
HCV-related rheumatic manifestations and therapeutic strategies 165
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1. 164
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 164
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 163
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 161
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 159
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 159
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. 157
Crioglobulinemia e linfoma in corso di infezione da HCV 157
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 156
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 155
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. 155
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 152
Effects of depletion of B cell by anti-CD20 monoclonal antibody in HCV+ mixed cryoglobulinemia (MC) and liver cirrhosis 151
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 147
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 146
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 145
Hepatitis C virus infection, malignancy and liver transplantation 144
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 144
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. 144
HCV AND lymphoma: Genetic and epigenetic factors 143
The Hepatitis C Virus Infection as a Systemic Disease 142
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 142
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 142
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 142
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 141
Comportamento dell'infezione da HCV in pazienti trapiantati per HCC complicante una cirrosi HCV-correlata 140
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 135
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 134
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label cohort study. 133
Hepatitis C virus lymphotrophism: lesson from a decade of studies 130
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 128
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. 126
Extrahepatic manifestations of chronic hepatitis C virus infection. 126
IL28B polymorphism as predictor of response to anti-HCV terapy in HCV-related mixed cryoglobulinemia syndrome 125
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 124
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 113
Modifications of Plasma PAF-AH activity in Patients with Chronic HCV infection 105
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma. 99
Prevalenza della ricombinazione Bcl-2 in pazienti con crioglobulinemia mista HCV correlata complicata o meno da linfoma.. 95
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma. 93
Prevalence of bcl-2 recombination in hepatitis C virus related mixed cryoglobulinemia with or without complicating B-cell lymphoma 92
Il riarrangiamento del bcl-2: un nuovo evento oncogenetico nei linfomi malt di soggetti HCV infetti 82
null 48
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 35
Totale 15.478
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022552 0 0 0 31 40 42 17 43 30 32 99 218
2022/20231.573 142 259 93 122 122 295 214 79 172 8 41 26
2023/2024542 23 74 97 26 28 105 8 109 11 28 14 19
2024/20254.281 141 426 254 611 1.353 673 47 239 170 91 152 124
2025/20264.284 525 526 265 315 429 176 482 194 465 300 88 519
2026/2027694 122 110 338 124 0 0 0 0 0 0 0 0
Totale 15.478